XINTELA

Xintela is a biopharma company that develops stem cell-based treatments focusing on osteoarthritis and difficult-to-heal leg ulcers and, through its wholly owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancer, such as triple-negative breast cancer and the brain tumor glioblastoma. The focus is on diseases that cause great suffering and lack effective medical treatment options... Xintela is a biomedical company working in the fields of stem cell therapy and targeted cancer therapy, with focus on indications with a high unmet medical need.

Also known as: xintela ab, Xintela AB (Publ)

Registration numbers: 556780-3480 (W)

VAT numbers: SE556780348001

Primary location: Lund Sweden